YALE COMPREHENSIVE CANCER CENTER

耶鲁大学癌症中心(YCC)于1974年被指定为NCI综合癌症中心。YCC已选择深刻改变其结构，以更好地促进其丰富的科学实力的临床翻译。在与NCI协商后，一个特别重要的组成部分是将医学肿瘤学的运营控制权转移到YCC，以增强中心对临床试验计划的影响。NCI的行政延期3年使这些变化成为可能。新任主任理查德·埃德尔森是一位成就卓著的翻译科学家，自2003年这些关键变化启动以来，他一直领导着该中心。超过6800万美元的机构支持使YCC得以加强设施并招聘60名外部教员，其中包括8个研究项目中5个项目的负责人、11个跨学科癌症疾病现场团队中的6个团队以及临床研究服务核心和方案审查委员会。战略科学招聘包括Joseph Schlesinger(设计受体酪氨酸激酶抑制剂的先驱，现在是信号转导计划的联合负责人)和Jeffrey Sklar(癌症分子诊断方面的领先创新者，现在是基因调节和功能基因组计划的联合负责人)。通过重新任命副主任来保持连续性，主任任命了新的基础和临床科学副主任。现在所有的研究计划都强调机械主题，临床部围绕三种主要的癌症治疗方式(小分子/抗癌药物、放射治疗和生物/免疫药物)进行组织，而不是局限于单一疾病地点。由于这些YCC结构和功能的集体变化，基于YCC科学的研究人员发起的临床试验的数量急剧增加。在YCC科学实验室附近，一座耗资4.6亿美元的新临床癌症塔已经开工建设。210名YCC成员来自27个耶鲁大学系和4所学校。自上次CCSG提交以来，经同行评审的癌症相关研究支持的年度直接成本增加了42%，从4300万美元增加到6200万美元，其中包括来自NCI的1530万美元。新的科学和临床研究人员的整合使YCC能够针对8套分组研究项目进行重点开发。YCC上一次获得批准是在1998年，它继续满足全面的指导方针。 根据NCI总费用2,560万美元的供资基数，YCC要求预算总费用为380万美元。

The Yale Cancer Center (YCC) was designated as an NCI Comprehensive Cancer Center in 1974. YCC has elected to profoundly alter its structure to better facilitate clinical translation of its abundant scientific strengths. A particularly important component, taken in consultation with the NCI, was relocation of operational control of Medical Oncology to YCC, to augment Center influence over the Clinical Trials Program. An administrative 3-year extension from the NCI enabled these changes. The new Director, Richard Edelson, an accomplished translational scientist, has led the Center since these pivotal changes were initiated in 2003. Over $68 million of institutional support permitted YCC to enhance facilities and recruit 60 external faculty members, including leaders of 5 of the 8 Research Programs, 6 of the 11 interdisciplinary cancer disease site teams and both the Clinical Research Services Core and Protocol Review Committee. Strategic scientific recruitments include Joseph Schlesinger (pioneer in the design of inhibitors of receptor tyrosine kinases and now Co-Leader of the Signal Transduction Program) and Jeffrey Sklar (a leading innovator in molecular diagnosis of cancer and now Co-Leader of the Gene Regulation and Functional Genomics Program). Preserving continuity by reappointing the Deputy Director, the Director appointed new Associate Directors of Basic and Clinical Sciences. All Research Programs now thematically stress mechanistic themes, and the Clinical Division has been organized around the three main cancer treatment modalities (small molecules/anticancer agents, radiation therapy, and biological/ immunological agents), rather than being confined to single disease sites. Due to these collective YCC structural and functional changes, the number of investigator initiated clinical trials, based on YCC science, have dramatically increased. Construction has begun on a $460M new Clinical Cancer Tower, proximal to the YCC scientific laboratories. The 210 YCC members come from 27 Yale Departments and 4 Schools. Since the last CCSG submission, total peer-reviewed, annual direct costs of cancer-relevant research support increased by 42%, from $43 million to $62 million, inclusive of $15.3 million from the NCI. Integration of the new scientific and clinical investigators has permitted the YCC to target 8 sets of grouped research projects for focused development. Last approved in 1998, YCC continues to satisfy guidelines for Comprehensiveness. Based on the NCI total cost funding base of $25.6 million, YCC is requesting a budget of $3.8 million in total costs.